Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
5
×
clinical trials
life sciences
national blog main
biotech
boston blog main
boston top stories
national top stories
allergan
eli lilly
fda
new york blog main
deals
europe blog main
merck
national
new york top stories
parkinson's disease
san francisco blog main
4d molecular therapeutics
acne
acorda therapeutics
agenus
alkermes
alzheimer's disease
amgen
ampyra
apokyn
apomorphine
astrazeneca
auris health
avexis
bayer
biohaven
biomx
bladder cancer
boston
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
What
treatment
5
×
fda
approved
drug
disease
medicines
new
nod
abbvie
acorda
adults
alkermes
allergan
alliance
antipsychotic
benefits
bio
biotech
caveats
class
commonly
companies
cope
designed
digital
editas
editing
effect
epidemic
episodes
exits
experimental
fatty
favor
frenzied
friday
gain
gene
genetic
gets
Language
unset
Current search:
treatment
×
abbvie
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms